Global Fatty Liver Treatment Market Growth Rate 2024, Forecast To 2033
8 Mar, 2024
The fatty liver treatment market is expected to grow from $22.17 billion in 2023 to $23.58 billion in 2024, with a 6.3% CAGR. By 2028, it's forecasted to reach $30.11 billion, driven by disease prevalence and innovation in therapeutics, with trends focusing on precision medicine and lifestyle modifications.
Global Fatty Liver Treatment Market Key Driver
The fatty liver treatment market is expected to see growth due to an increase in alcohol consumption worldwide. Kirin Holdings Company Limited reports a rise in global beer consumption, indicating a higher risk of fatty liver disease and driving demand for treatment options.
Get A Free Sample Of The Global Fatty Liver Treatment Market ReportGlobal Fatty Liver Treatment Market Segments
The fatty liver treatment market covered in this report is segmented –
1) Treatment Type:Anti-Rejection Drugs Or Immunosuppressants, Chemotherapy Drugs, Targeted Therapy, Vaccines, Anti-Viral Drugs
2) Disease Type:Hepatitis, Liver Cancer, Non-Alcoholic Fatty Liver Disease, Other Diseases
3) End User:Hospitals, Ambulatory Surgery Centers, Other End Users
By Geography: The countries covered in the fatty liver treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
North America was the largest region in the fatty liver treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fatty liver treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Fatty Liver Treatment Industry Players
Pfizer Inc.; Johnson & Johnson Services Inc.; Hoffmann La Roche Ltd.; AstraZeneca plc; Merck & Co. Inc.; AbbVie Inc.; Bayer AG; Novartis AG; Sanofi S.A.; The Bristol-Myers Squibb Company; GlaxoSmithkline plc; Mitsubishi Chemical Holdings; Takeda Pharmaceutical Company Limited; Gilead Sciences Inc.; Novo Nordisk A/S; Eisai Co. Ltd.; Zydus Lifesciences Limited; Glenmark Pharmaceuticals Limited; GW Pharmaceuticals Limited; Retrophin Inc.; Alnylam Pharmaceuticals Inc.; Intercept Pharmaceuticals Inc.; AbbKine Scientific Co. Ltd.; Daewoong Co. Ltd.; Madrigal Pharmaceuticals Inc.; Orchid Chemicals & Pharmaceuticals Limited; Genfit; NGM Biopharmaceuticals Inc.; Cardax Inc.; Conatus Pharmaceuticals Inc.; Limerick Biopharma Inc.
Get The Full Global Fatty Liver Treatment Market Report
Fatty Liver Treatment Market Overview
Fatty liver disease is a condition in which fat builds up in the liver, causing various symptoms and complications. Fatty liver treatment refers to the multiple strategies, interventions, and actions to address and manage fatty liver disease.